Home / Health / New Drug Combo Eradicates Pancreatic Tumors in Mice
New Drug Combo Eradicates Pancreatic Tumors in Mice
30 Jan
Summary
- A novel drug combination therapy led to complete tumor regression in mice.
- The experimental treatment showed no signs of tumor relapse in animal models.
- Researchers suggest these findings could guide future human clinical trials.
Pancreatic cancer, known for its high fatality rate, is often detected late, making treatment challenging. A recent study conducted by researchers in Spain has yielded significant breakthroughs using a new drug combination therapy. In experiments involving genetically engineered mice and patient-derived tumor xenografts, this combination therapy resulted in the complete regression of tumors.
Crucially, the study, published in the journal PNAS, reported no instances of tumor relapse following treatment. The researchers emphasized that the combination therapy was well-tolerated, with no major side effects observed in the animal models. This success offers a beacon of hope for improving survival rates in pancreatic ductal adenocarcinoma (PDAC).
Globally, pancreatic cancer accounts for a disproportionately high number of cancer deaths relative to its incidence. In 2022, over 500,000 people were diagnosed worldwide, with nearly 470,000 deaths. The findings from the Spanish research are expected to guide the development of new clinical trials that may offer substantial benefits to PDAC patients.
